Based on our findings and previous experience (35, 36), we substitute VWF containing concentrate in all PAH patients with confirmed or suspected VWS type 1 or 2, prior to, during and after invasive procedures or surgery, and also during VA-ECMO while being heparinized. The gene discussed is VWF; the disease is pulmonary arterial hypertension.